Payment overview · 2025
General Payments
$216.60
12 reported records · 5 companies
Healthcare provider profile · identity verified
Billy Mack Pickering, MD
Allopathic & Osteopathic Physicians|Family Medicine · SEMINARY, MS · NPI 1487762787
Verified facts
What the public records show
CMS Open Payments records show Billy Mack Pickering, MD received $216.60 in general payments during 2025 across 12 reported records.
PFIZER INC. accounted for 25.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $56.00 | 25.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.28 | 23.7% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $46.88 | 21.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.27 | 20.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.17 | 8.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $216.60 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $56.00 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.28 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.28 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $46.88 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.27 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.27 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $41.25 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 125 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
125 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 705 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 604 | 124 |
| Gabapentin | Gabapentin | 523 | 133 |
| Pantoprazole Sodium | Pantoprazole Sodium | 474 | 114 |
| Metformin Hcl | Metformin Hcl | 361 | 78 |
| Omeprazole | Omeprazole | 346 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 343 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 338 | 69 |
| Tizanidine Hcl | Tizanidine Hcl | 273 | 69 |
| Furosemide | Furosemide | 266 | 77 |
| Famotidine | Famotidine | 257 | 67 |
| Losartan Potassium | Losartan Potassium | 256 | 53 |
| Irbesartan | Irbesartan | 251 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 248 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 235 | 42 |
| Allopurinol | Allopurinol | 216 | 48 |
| Potassium Chloride | Potassium Chloride | 210 | 54 |
| Carvedilol | Carvedilol | 209 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 202 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 192 | 37 |
| Trazodone Hcl | Trazodone Hcl | 185 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 171 | 34 |
| Alprazolam | Alprazolam | 162 | 28 |
| Buspirone Hcl | Buspirone Hcl | 162 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 157 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 33 |
| Meloxicam | Meloxicam | 135 | 40 |
| Sertraline Hcl | Sertraline Hcl | 135 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 36 |
| Glimepiride | Glimepiride | 128 | 31 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 126 | 31 |
| Ozempic | Semaglutide | 125 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 120 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 102 | 22 |
| Cefuroxime | Cefuroxime Axetil | 102 | 78 |
| Synthroid | Levothyroxine Sodium | 102 | 21 |
| Montelukast Sodium | Montelukast Sodium | 100 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 33 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 97 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 24 |
| Warfarin Sodium | Warfarin Sodium | 89 | 13 |
| Lisinopril | Lisinopril | 88 | 23 |
| Celecoxib | Celecoxib | 87 | 18 |
| Fenofibrate | Fenofibrate | 86 | 17 |
| Simvastatin | Simvastatin | 84 | 18 |
| Mounjaro | Tirzepatide | 83 | 13 |
| Valsartan | Valsartan | 82 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 18 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 81 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 77 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 18 |
| Tramadol Hcl | Tramadol Hcl | 73 | 18 |
| Farxiga | Dapagliflozin Propanediol | 69 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 67 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 15 |
| Xarelto | Rivaroxaban | 65 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 30 |
| Pregabalin | Pregabalin | 63 | 17 |
| Meclizine Hcl | Meclizine Hcl | 62 | 16 |
| Spironolactone | Spironolactone | 62 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 11 |
| Ezetimibe | Ezetimibe | 59 | suppressed |
| Eliquis | Apixaban | 57 | 15 |
| Alendronate Sodium | Alendronate Sodium | 56 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 55 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 13 |
| Fluconazole | Fluconazole | 53 | 30 |
| Nebivolol Hcl | Nebivolol Hcl | 52 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 52 | suppressed |
| Azithromycin | Azithromycin | 51 | 43 |
| Clonazepam | Clonazepam | 51 | 11 |
| Mirtazapine | Mirtazapine | 48 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | 19 |
| Lorazepam | Lorazepam | 47 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 38 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 43 | 29 |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | suppressed |
| Prednisone | Prednisone | 42 | 23 |
| Nitroglycerin | Nitroglycerin | 41 | 17 |
| Diltiazem 24hr Er | Diltiazem Hcl | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Ranolazine Er | Ranolazine | 37 | suppressed |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 19 |
| Nystatin | Nystatin | 24 | 14 |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Cefdinir | Cefdinir | 23 | 18 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Finasteride | Finasteride | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 16 |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Clonidine | Clonidine | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Tretinoin | Tretinoin | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $216.60 · 12 records | PFIZER INC. | NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, XIFAXAN, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error